Indian blanket brownfield ban call brings fresh headwinds for FDI
This article was originally published in Scrip
An Indian Parliamentary panel has recommended a "blanket ban" on foreign direct investment (FDI) in brownfield pharmaceutical projects in the country, claiming "danger" to health and intellectual property rights aspects arising from such investments including access and affordability of medicines, as well as the "elbowing" out of the domestic industry and undue pressures on TRIPS arrangements.
You may also be interested in...
Draft appears set for rocky path ahead; Pink Sheet highlights five controversial elements ahead of Aug 30 stakeholders meeting.
India has eased foreign direct investment (FDI) norms in the pharmaceutical sector – reforms that are expected to buoy foreign capital inflows and investor sentiment, especially private equity, though some opponents claim it may potentially have a dire impact on India's future medicines security.
Syngene’s COO, Mahesh Bhalgat, said the firm is better placed than some peers to serve clients for biologics-based advanced therapies and address the cost element for new modalities like mRNA. He also outlines the research, development and manufacturing services company's capabilities in oligonucleotide-based therapeutics, an area that's seeing growing interest.